| Mark Fishman | |
| Citizenship: | United States |
| Fields: | Medicine, Cardiology |
| Workplaces: | Novartis Institutes of BioMedical Research, Massachusetts General Hospital, Harvard Medical School |
| Alma Mater: | Yale College, Harvard Medical School |
| Known For: | pioneering Zebrafish research in cardiology |
| Awards: | Institute of Medicine member, Fellow of the American Academy of Arts and Sciences |
Mark Fishman is an American cardiologist, a professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service service at the Massachusetts General Hospital for patients with complex medical disorders.[1] A researcher and clinician in cardiology, he is the previous president of the Novartis Institutes for BioMedical Research (NIBR),[2] the main research arm of Novartis Pharmaceuticals.[3]
Fishman was appointed president of the newly founded Novartis Institutes for BioMedical Research in 2002 to implement a new strategy in Novartis' global drug discovery effort.[4] He is the author of over 100 publications[5] and known for pioneering research using the zebrafish as a means of visualizing the development of the circulatory system and as a model for human disease.[6] [7] [8]
He was previously a professor of medicine at Harvard Medical School, chief of cardiology at Massachusetts General Hospital, and director of the Cardiovascular Research Center at Massachusetts General Hospital. He is a fellow of the National Academy of Arts and Sciences and a member of the National Academy of Sciences, Institute of Medicine.[9]
After being the head of Novartis for 13 years, he decided to retire in 2016[10] and became professor at Harvard and Chief at MGH[1]